netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Denosumab found 20 matches

Formulary items 2 matches
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Denosumab  (Prolia®) Endocrine system - Denosumab - 06.06.02
  Denosumab  (XGEVA®) Endocrine system - Denosumab - 06.06.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section LSCMMG: Denosumab as a second line treatment option for the prevention of osteoporotic fragility fractures position statement (06.06.02)
link in drug section LSCMMG: Shared care guideline (Denosumab 120mg injection (Xgeva®)) (06.06.02)
link in drug section LSCMMG: Shared care guideline (Denosumab 60mg injection (Prolia®)) (06.06.02)
link in drug section MHRA Drug Safety Update Aug 2020: Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment (06.06.02)
link in drug section MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal (06.06.02)
link in drug section MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal (06.06.02)
link in drug section MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate (06.06.02)
link in drug section MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation  (06.06.02)
link in drug section MHRA Drug Safety Update May 2022: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab: updated recommendations (06.06.02)
link in drug section MHRA: Denosumab: updated recommendations (06.06.02)
link in drug section NICE TA204: Osteoporotic fractures - denosumab  (06.06.02)
link in drug section NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (06.06.02)

SubSection Titles / notes  
Denosumab - (06.06.02)

 
netFormulary